FRS2 and triple-negative breast carcinoma: PD 173074 significantly reduces the proliferation of triple negative breast cancer cell SUM185PE (harboring a FGFR3-TACC3 fusion) and also seems to be involved in cell cycle arrest within the G1 phase, apoptosis, and decrease of fibroblast growth factor receptor substrate 2 (FRS2) and AKT activation [54].